TransMedics Group (NASDAQ:TMDX) Trading Down 6.1%

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price dropped 6.1% during trading on Wednesday . The company traded as low as $87.56 and last traded at $87.65. Approximately 447,535 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 681,154 shares. The stock had previously closed at $93.31.

Analyst Ratings Changes

TMDX has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Oppenheimer boosted their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, Piper Sandler began coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an “overweight” rating and a $95.00 target price on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $102.00.

TransMedics Group Stock Down 3.5 %

The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The company’s 50 day simple moving average is $82.97 and its 200 day simple moving average is $72.98.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. The business’s quarterly revenue was up 158.6% on a year-over-year basis. On average, research analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 736 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Edward M. Basile sold 7,157 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the completion of the transaction, the director now owns 8,350 shares in the company, valued at $721,273. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 736 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. Insiders sold 119,408 shares of company stock valued at $10,182,881 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Wasatch Advisors LP acquired a new position in TransMedics Group during the first quarter worth $32,162,000. Allspring Global Investments Holdings LLC boosted its holdings in TransMedics Group by 3.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after purchasing an additional 21,737 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in TransMedics Group by 3.4% during the first quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after purchasing an additional 372 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in TransMedics Group in the fourth quarter valued at $603,000. Finally, Vanguard Group Inc. lifted its stake in TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after acquiring an additional 50,673 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.